Search
Mangafodipir
go.drugbank.com/drugs/DB06796ApprovedInvestigationalWithdrawnThis drug is made up of paramagnetic manganese (II) ions combined with the chelating agent _fodipir_ (dipyridoxyl diphosphate, DPDP). … Teslascan has been removed from the Drug Product List by FDA in 2003, and withdrawn from the European market in 2012.
Pentoxifylline
go.drugbank.com/drugs/DB00806ApprovedInvestigational[A226608] Pentoxifylline has been marketed in Europe since 1972; PTX extended-release tablets sold under the trade name TRENTAL by US Pharm Holdings were first approved by the FDA on Aug 30, 1984, but … A branded product, PENTOXIL, marketed by Upsher-Smith Laboratories, and generic forms marketed by Valeant Pharmaceuticals and APOTEX have been available since the late 1990s.[L30300]
Ranibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigationalIn order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use. … [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO.
Protamine sulfate
go.drugbank.com/drugs/DB09141ApprovedInvestigationalDespite the relative importance of protamine sulfate's medical indication, the medication can notoriously cause a variety of potentially rare but genuinely severe adverse effects that include systemic … Since it's earliest discovery in salmon rine sperm heads in the late 1800's to its formal introduction via US FDA approval in 1939, protamine sulfate has occupied an important therapeutic niche as perhaps
Gadodiamide
go.drugbank.com/drugs/DB00225ApprovedInvestigational[A263086,A263091] GBCAs constitute the largest group of MR agents, and they are thought to be safer than nonionic iodinated contrast agents. … [A263096] Approved by the FDA in 1993, gadodiamide is the first non-ionic GBCA to be used.
Magnesium cation
go.drugbank.com/drugs/DB01378ApprovedInvestigationalNutraceuticalWithdrawnMilk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn. … When taken internally by mouth as a laxative, the osmotic force of the magnesia suspension acts to draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend
Mixtures: MAGVEL 365 MG GRANÜL İÇEREN SAŞE, 10 ADET, MAGVEL 365 MG GRANÜL İÇEREN SAŞE, 20 ADETDeflazacort
go.drugbank.com/drugs/DB11921ApprovedIt is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA. … [A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7.
Finafloxacin
go.drugbank.com/drugs/DB09047ApprovedWithdrawnFinafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014. … Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.
Unexpanded umbilical cord-derived allogeneic CD34- hematopoietic stem cells
go.drugbank.com/drugs/DB28348Approved[L54106] Zemcelpro also contains [dorocubicel], a preparation CD34+ HSCs derived from the same cord blood sample and expanded _ex vivo_ using [UM-171].
Itraconazole
go.drugbank.com/drugs/DB01167ApprovedInvestigational[L50051] Itraconazole was first approved in the US in 1992 [L50056] and is available orally. … While the intravenous formulation of the drug was formerly available, it was discontinued in the US in 2007.[A263232]